A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Description

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Conditions

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Condition
Pancreatic Ductal Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Santa Monica

UCLA, Santa Monica, California, United States, 90404

South Pasadena

City of Hope Medical Group, South Pasadena, California, United States, 91030

Denver

Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States, 80218

Orlando

Florida Cancer Specialists Lake Nona Drug Development Unit, Orlando, Florida, United States, 32827

Atlanta

Emory University School of Medicine, Atlanta, Georgia, United States, 30322

Indianapolis

Community Health Network, Indianapolis, Indiana, United States, 46250

Baltimore

Johns Hopkins Hospital, Baltimore, Maryland, United States, 21287

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

Grand Rapids

START Midwest, Grand Rapids, Michigan, United States, 49546

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • * Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
  • * Have an ECOG performance status of ≤ 1
  • * Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease
  • * Participants with asymptomatic or treated CNS disease may be eligible.
  • * Have known active CNS metastases and/or carcinomatous meningitis.
  • * Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.
  • * Have significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.
  • * Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
  • * Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV).
  • * Have other active malignancy unless in remission with life expectancy greater than (\>) 2 years.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2029-03